10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,739,813 | $73,193,933 | -13% | 2.78% |
| 2. | Alkeon Capital Management Panayotis Takis Sparaggis | 1,686,716 | $70,960,143 | -44% | 0.14% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,576,114 | $66,307,116 | 0.7% | |
| 4. | Vestal Point Capital Ryan Wilder | 1,500,000 | $63,105,000 | +100% | 3.74% |
| 5. | Alyeska Investment Group Anand Parekh | 1,439,740 | $60,569,862 | +24% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | Officer, Director | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | Officer, Director | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | Officer, Director | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | Large Shareholder, Other | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | Officer | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.40 | 1,785 | 106,169 | 2025-03-06 | Filing | ||
| $42.10 | 6,028 | 265,238 | 2025-03-03 | Filing | ||
| $42.10 | 12,846 | 75,287 | 2025-03-03 | Filing | ||
| $42.10 | 8,945 | 71,922 | 2025-03-03 | Filing | ||
| $42.10 | 14,439 | 107,766 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,034,862 | $422,166,645 | 0% | |
| 2. | 6,536,517 | $274,991,271 | 0% | |
| 3. | 4,298,003 | $180,816,986 | 0.53% | |
| 4. | 2,722,624 | $114,540,792 | 0% | |
| 5. | 2,457,543 | $103,388,833 | 0.01% |
News See All
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript February 13, 2025Ultragenyx Pharmaceutical Inc. misses on earnings expectations.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72.
5 NASDAQ Stocks with Biggest Upside
Based on 12 Wall Street analysts’ ratings in the last three months, Rivian Automotive, Inc. (NASDAQ:RIVN) has a consensus rating of Moderate Buy.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.